Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2903 - Clinical impact of programmed death ligand-1 and -2 expression after platinum based chemotherapy in metastatic gastric cancer

Date

09 Sep 2017

Session

Poster display session

Presenters

Ji Hyun Yang

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

J.H. Yang1, S. Park2, E.K. Joung1, M.A. Lee1, S.Y. Roh1, I. Kim1

Author affiliations

  • 1 Department Of Internal Medicine, Division Of Medical Oncology, Seoul St. Mary's Hospital, 137-701 - Seoul/KR
  • 2 Department Of Internal Medicine, Division Of Medical Oncology, Seoul St. Mary's Hospital, Seoul/KR
More

Resources

Abstract 2903

Background

The effect of chemotherapy on programmed death ligand-1 (PD-L1) and PD-L2 expression is not well known. Therefore we aimed to investigate the effect of chemotherapy to PD-L1/2 expression in metastatic gastric cancer (mGC).

Methods

We evaluated the PD-L1 and 2 expression of 63 patients with paired tumor tissue before and after 3 to 4 cycles of palliative first line platinum-based chemotherapy. PD-L1/2 expression was detected by immunohistochemistry(IHC) method in paired tumor specimens.

Results

There were no significant differences in PD-L1 and PD-L2 expression across various clinicopathological parameters. The detection of PD-L1 on tumor cells decreased from 58% to 38% after chemotherapy (p = 0.028), but not with PD-L2 (from 43% to 36%). Among patients with objective response (CR and PR), PD-L1 expression decreased with statistical significance (p = 0.033), but not among patients with SD and PD (p = 0.275). In univariate and multivariate analysis, patients with positive PD-L1 at the pre-chemotherapy showed better progression free survival (PFS, hazard ratio [HR]=0.42, p = 0.014). In contrary, after chemotherapy, patients with positive PD-L1 showed decreased PFS (HR = 1.97, p = 0.023). And pre-chemotherapy PD-L1 statuses didn’t have any correlation with OS difference, however, post-chemotherapy negative PD-L1 prolonged OS (HR = 1.92, p = 0.047). PD-L2 statuses had no difference of PFS and OS before and after chemotherapy. Univariate and Multivariate analysis showed that negative to positive change and positive to negative change of PD-L1 expression was associated with poorer PFS (HR = 0.030, p = 0.03) and better PFS (HR = 0.02, p = 0.024), respectively.

Conclusions

Our data suggests that chemotherapy may have an effect on the status of PD-L1/L2 expression. PD-L1/L2 expression may change during chemotherapy, so we suggest monitoring the pattern of change through serial tumor samples to reflect the correct status of PD-L1 expression.

Clinical trial identification

Legal entity responsible for the study

In-Ho Kim

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.